EGF and breast cancer: Other studies found that apl-1 inhibited the Wnt/β-catenin pathway through the proteasomal degradation of β-catenin [44] and the epidermal growth factor (EGF)-dependent proliferation of breast cancer cells (MCF-7 and ZR-75-1), probably by blocking the phosphorylation of EGF receptor [45].